Applied Dna Sciences INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
BNB Plus Corp. calls a Special Meeting to seek stockholder approval for a reverse stock split, aiming to regain Nasdaq compliance and facilitate strategic alternatives amidst delisting concerns.
BNB Plus Corp., formerly Applied DNA Sciences, Inc., announced its name change effective November 13, 2025, signaling a strategic shift towards a BNB-based digital asset treasury strategy.
Applied DNA Sciences calls a Special Meeting to approve warrant exercises, increase authorized shares, and expand its equity incentive plan to support its new BNB digital asset strategy.
Applied DNA Sciences is holding its 2025 Annual Meeting of Stockholders virtually on May 22, 2025, to vote on key proposals including a reverse stock split, warrant exercises, and an amendment to the equity incentive plan.
Applied DNA Sciences reminds shareholders to vote on the Warrant Exercise Proposal before the reconvened Special Meeting on February 14, 2025, following an adjournment due to lack of quorum.
DEFA14A: Applied DNA Sciences Seeks Stockholder Approval for Warrant Exercisability at Special Meeting
Applied DNA Sciences is holding a special stockholder meeting on January 23, 2025, to vote on the exercisability of certain common stock purchase warrants issued in connection with a prior securities offering.
DEF 14A: Applied DNA Sciences Seeks Stockholder Approval for Warrant Exercisability at Special Meeting
Applied DNA Sciences is holding a special virtual meeting on January 23, 2025, to seek stockholder approval for the exercisability of certain common stock purchase warrants issued in connection with a recent securities offering.
DEFA14A: Applied DNA Sciences Seeks Stockholder Approval for Reverse Stock Split and Warrant Exercisability
Applied DNA Sciences is holding its annual meeting to vote on director elections, auditor ratification, a potential reverse stock split, and approval of warrant exercisability.
DEF 14A: Applied DNA Sciences Sets Date for 2024 Annual Stockholders Meeting, Proposes Reverse Stock Split
Applied DNA Sciences will hold its 2024 Annual Meeting of Stockholders virtually on September 30, 2024, to vote on director elections, auditor ratification, a potential reverse stock split, and warrant exercises.
Applied DNA Sciences is seeking stockholder approval for the exercisability of certain common stock purchase warrants issued in connection with a securities offering on May 28, 2024.
Applied DNA Sciences is holding a special meeting to seek stockholder approval for the exercisability of warrants issued in connection with a recent securities offering.
Applied DNA Sciences is seeking stockholder approval for several key proposals, including warrant repricing, a reverse stock split, and an increase in authorized shares for its equity incentive plan.
Applied DNA Sciences is holding a special meeting to seek stockholder approval for several key proposals, including warrant-related actions, a potential reverse stock split, and an amendment to its equity incentive plan.